Forxiga (BioDeep_00000827206)
代谢物信息卡片
Dapagliflozin Propanediol
化学式: C24H35ClO9 (502.196949)
中文名称: 达格列净一水丙二醇
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl.CC(CO)O.O
InChI: 3-
描述信息
C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent
D007004 - Hypoglycemic Agents > D000077203 - Sodium-Glucose Transporter 2 Inhibitors
C471 - Enzyme Inhibitor > C98083 - SGLT2 Inhibitor
同义名列表
2 个代谢物同义名
数据库引用编号
5 个数据库交叉引用编号
- ChEBI: CHEBI:85079
- PubChem: 24906252
- ChEMBL: CHEMBL2103802
- CAS: 1700615-13-9
- CAS: 960404-48-2
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Soo Lim, Seung-Hwan Lee, Kyung-Wan Min, Chang Beom Lee, Sang Yong Kim, Hye Jin Yoo, Nan Hee Kim, Jae Hyeon Kim, Seungjoon Oh, Jong Chul Won, Hyuk Sang Kwon, Mi Kyung Kim, Jung Hwan Park, In-Kyung Jeong, Sungrae Kim. A multicentre, double-blind, placebo-controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add-on therapy in type 2 diabetic patients treated with metformin and dapagliflozin.
Diabetes, obesity & metabolism.
2024 Jun; 26(6):2188-2198. doi:
10.1111/dom.15526. [PMID: 38425186] - Guillem Cuatrecasas, Francisco De Cabo, M José Coves, Ioana Patrascioiu, Gerardo Aguilar, Gabriel Cuatrecasas, Sonia March, Marta Calbo, Olga Rossell, Mariona Balfegó, Camila Benito, Silvana Di Gregorio, Pilar Garcia Lorda, Elena Muñoz. Dapagliflozin added to metformin reduces perirenal fat layer in type 2 diabetic patients with obesity.
Scientific reports.
2024 05; 14(1):10832. doi:
10.1038/s41598-024-61590-6. [PMID: 38734755] - Zijie Jin, Ruotong Yin, Yan Yuan, Chen Zheng, Peng Zhang, Yalin Wang, Hongbo Weng. Dapagliflozin ameliorates hepatic steatosis via suppressing LXRα-mediated synthesis of lipids and bile acids.
Biochemical pharmacology.
2024 May; 223(?):116167. doi:
10.1016/j.bcp.2024.116167. [PMID: 38527558] - Yi-Hui Wang, Dong-Yuan Chang, Ming-Hui Zhao, Min Chen. Dapagliflozin Alleviates Diabetic Kidney Disease via Hypoxia Inducible Factor 1α/Heme Oxygenase 1-Mediated Ferroptosis.
Antioxidants & redox signaling.
2024 Mar; 40(7-9):492-509. doi:
10.1089/ars.2022.0169. [PMID: 37276148] - Linli Zhang, Fan Zhang, Yan Bai, Liuyan Huang, Yifei Zhong, Xianwen Zhang. Effects of sodium-glucose cotransporter-2 (SGLT-2) inhibitors on serum uric acid levels in patients with chronic kidney disease: a systematic review and network meta-analysis.
BMJ open diabetes research & care.
2024 Jan; 12(1):. doi:
10.1136/bmjdrc-2023-003836. [PMID: 38238025] - Mei-Zi Wang, Yu-Feng Cai, Qi-Jun Fang, Ying-Lu Liu, Jie Wang, Jia-Xin Chen, Yan Fu, Bing-Ying Wan, Yue Tu, Wei Wu, Yi-Gang Wan, Geng-Lin Mu. Inhibition of ferroptosis of renal tubular cells with total flavones of Abelmoschus manihot alleviates diabetic tubulopathy.
Anatomical record (Hoboken, N.J. : 2007).
2023 12; 306(12):3199-3213. doi:
10.1002/ar.25123. [PMID: 36440653] - Jingjing Da, Yongjie Xu, Ying Tan, Jiqin Zhang, Jiali Yu, Jianqiu Zhao, Qingen Da, Fuxun Yu, Yan Zha. Central administration of Dapagliflozin alleviates a hypothalamic neuroinflammatory signature and changing tubular lipid metabolism in type 2 diabetic nephropathy by upregulating MCPIP1.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
2023 Dec; 168(?):115840. doi:
10.1016/j.biopha.2023.115840. [PMID: 37931516] - Liangzhi Zhang, Hengjun Lin, Xudong Yang, Jipeng Shi, Xiusheng Sheng, Lifeng Wang, Ting Li, Helong Quan, Xia Zhai, Wei Li. Effects of dapagliflozin monotherapy and combined aerobic exercise on skeletal muscle mitochondrial quality control and insulin resistance in type 2 diabetes mellitus rats.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
2023 Nov; 169(?):115852. doi:
10.1016/j.biopha.2023.115852. [PMID: 37944441] - Zhenwang Zhang, Ping Ni, Mingqiu Tang, Yi Song, Chao Liu, Baoqing Zhao. Dapagliflozin alleviates renal podocyte pyroptosis via regulation of the HO‑1/NLRP3 axis.
Molecular medicine reports.
2023 Nov; 28(5):. doi:
10.3892/mmr.2023.13087. [PMID: 37711056] - Jiangjun Wei, Fangyan Tan, Xianglin Long, Qinghua Fang, Yao Wang, Jing Wang, JiaCheng He, Xin Yuan, Jianlin Du. RNA-Seq transcriptome analysis of renal tissue from spontaneously hypertensive rats revealed renal protective effects of dapagliflozin, an inhibitor of sodium-glucose cotransporter 2.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
2023 Oct; 189(?):106531. doi:
10.1016/j.ejps.2023.106531. [PMID: 37479045] - Feixing Li, Huixian Li, Fangjiang Li, Xiaobo Xiong, Yang Gao, Ai'ai Zhang, Jianying Song, Wei Han, Binyu Niu, Huiqing Liang. The effect of dapagliflozin on anemia in elderly patients with heart failure by bioinformatics analysis.
Technology and health care : official journal of the European Society for Engineering and Medicine.
2023 Sep; ?(?):. doi:
10.3233/thc-230563. [PMID: 37781829] - Changlun Hu, Tianhua Qu, Lin Li, Yi Huang, Huabao Liu, Chunyan Rao. Therapeutic outcome of dapagliflozin in patients with type 2 diabetes and non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
African health sciences.
2023 Jun; 23(2):416-421. doi:
10.4314/ahs.v23i2.48. [PMID: 38223613] - Glenn M Chertow, Ricardo Correa-Rotter, Priya Vart, Niels Jongs, John J V McMurray, Peter Rossing, Anna Maria Langkilde, C David Sjöström, Robert D Toto, David C Wheeler, Hiddo J L Heerspink. Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA-CKD Trial.
Journal of the American Heart Association.
2023 May; 12(9):e028739. doi:
10.1161/jaha.122.028739. [PMID: 37119064] - Bin Feng, Fan Yang, Jie Liu, Qichao Sun, Ran Meng, Dalong Zhu. Amelioration of diabetic kidney injury with dapagliflozin is associated with suppressing renal HMGB1 expression and restoring autophagy in obese mice.
Journal of diabetes and its complications.
2023 03; 37(3):108409. doi:
10.1016/j.jdiacomp.2023.108409. [PMID: 36731146] - Anna Veelen, Charlotte Andriessen, Yvo Op den Kamp, Edmundo Erazo-Tapia, Marlies de Ligt, Julian Mevenkamp, Johanna A Jörgensen, Esther Moonen-Kornips, Gert Schaart, Russell Esterline, Bas Havekes, Jan Oscarsson, Vera B Schrauwen-Hinderling, Esther Phielix, Patrick Schrauwen. Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on substrate metabolism in prediabetic insulin resistant individuals: A randomized, double-blind crossover trial.
Metabolism: clinical and experimental.
2023 03; 140(?):155396. doi:
10.1016/j.metabol.2022.155396. [PMID: 36592688] - Shakta Mani Satyam, Laxminarayana Kurady Bairy, Prakashchandra Shetty, P Sainath, Sanjay Bharati, Akheruz Zaman Ahmed, Varun Kumar Singh, A J Ashwal. Metformin and Dapagliflozin Attenuate Doxorubicin-Induced Acute Cardiotoxicity in Wistar Rats: An Electrocardiographic, Biochemical, and Histopathological Approach.
Cardiovascular toxicology.
2023 02; 23(2):107-119. doi:
10.1007/s12012-023-09784-8. [PMID: 36790727] - Emil List Larsen, Andreas Andersen, Laura K Kjær, Mie K Eickhoff, Marie Frimodt-Møller, Frederik Persson, Peter Rossing, Jens Lykkesfeldt, Filip K Knop, Tina Vilsbøll, Jørgen Rungby, Henrik E Poulsen. Effects of two- and twelve-weeks sodium-glucose cotransporter 2 inhibition on DNA and RNA oxidation: two randomized, placebo-controlled trials.
Free radical research.
2023 Feb; 57(2):140-151. doi:
10.1080/10715762.2023.2213820. [PMID: 37171199] - Shilong Xiong, Donghua Mo, Yingjun Wu, Peng Wu, YuanMing Hu, Fang Gong. The effect of dapagliflozin on myocardial ischemia-reperfusion injury in diabetic rats.
Canadian journal of physiology and pharmacology.
2023 Feb; 101(2):80-89. doi:
10.1139/cjpp-2022-0045. [PMID: 36621925] - Mohammed F Gholam, Lauren P Liu, Louis A Searcy, Nancy D Denslow, Abdel A Alli. Dapagliflozin Treatment Augments Bioactive Phosphatidylethanolamine Concentrations in Kidney Cortex Membrane Fractions of Hypertensive Diabetic db/db Mice and Alters the Density of Lipid Rafts in Mouse Proximal Tubule Cells.
International journal of molecular sciences.
2023 Jan; 24(2):. doi:
10.3390/ijms24021408. [PMID: 36674924] - Nandi Bao, Xiaoli Liu, Xiaoling Zhong, Shuangshuang Jia, Ning Hua, Li Zhang, Guoxin Mo. Dapagliflozin-affected endothelial dysfunction and altered gut microbiota in mice with heart failure.
PeerJ.
2023; 11(?):e15589. doi:
10.7717/peerj.15589. [PMID: 37520255] - Deng Lin, Yuling Song. Dapagliflozin Presented Nonalcoholic Fatty Liver Through Metabolite Extraction and AMPK/NLRP3 Signaling Pathway.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
2023 Jan; 55(1):75-84. doi:
10.1055/a-1970-3388. [PMID: 36495240] - Yvo J M Op den Kamp, Anne Gemmink, Marlies de Ligt, Bas Dautzenberg, Esther Kornips, Johanna A Jorgensen, Gert Schaart, Russell Esterline, Diego A Pava, Joris Hoeks, Vera B Schrauwen-Hinderling, Sander Kersten, Bas Havekes, Timothy R Koves, Deborah M Muoio, Matthijs K C Hesselink, Jan Oscarsson, Esther Phielix, Patrick Schrauwen. Effects of SGLT2 inhibitor dapagliflozin in patients with type 2 diabetes on skeletal muscle cellular metabolism.
Molecular metabolism.
2022 12; 66(?):101620. doi:
10.1016/j.molmet.2022.101620. [PMID: 36280113] - Hager H Shaaban, Ibrahim Alzaim, Ahmed El-Mallah, Rania G Aly, Ahmed F El-Yazbi, Ahmed Wahid. Metformin, pioglitazone, dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms.
Life sciences.
2022 Nov; 308(?):120956. doi:
10.1016/j.lfs.2022.120956. [PMID: 36103959] - Ahmed M Fleifel, Ayman A Soubh, Dalaal M Abdallah, Kawkab A Ahmed, Hanan S El-Abhar. Preferential effect of Montelukast on Dapagliflozin: Modulation of IRS-1/AKT/GLUT4 and ER stress response elements improves insulin sensitivity in soleus muscle of a type-2 diabetic rat model.
Life sciences.
2022 Oct; 307(?):120865. doi:
10.1016/j.lfs.2022.120865. [PMID: 35934057] - Ke Lin, Na Yang, Wu Luo, Jin-Fu Qian, Wei-Wei Zhu, Shi-Ju Ye, Chen-Xin Yuan, Di-Yun Xu, Guang Liang, Wei-Jian Huang, Pei-Ren Shan. Direct cardio-protection of Dapagliflozin against obesity-related cardiomyopathy via NHE1/MAPK signaling.
Acta pharmacologica Sinica.
2022 Oct; 43(10):2624-2635. doi:
10.1038/s41401-022-00885-8. [PMID: 35217813] - Eman M Khalaf, Hanan M Hassan, Ahmed M El-Baz, Ahmed Shata, Ahmed E Khodir, Mahmoud E Yousef, Rehab Mohamed Elgharabawy, Nehal A Nouh, Safaa Saleh, Mashael M Bin-Meferij, Attalla F El-Kott, Mohamed M A El-Sokkary, Hanan Eissa. A novel therapeutic combination of dapagliflozin, Lactobacillus and crocin attenuates diabetic cardiomyopathy in rats: Role of oxidative stress, gut microbiota, and PPARγ activation.
European journal of pharmacology.
2022 Sep; 931(?):175172. doi:
10.1016/j.ejphar.2022.175172. [PMID: 35944619] - Elisa Lazzaroni, Maria Elena Lunati, Laura Montefusco, Ida Pastore, Enrica Chebat, Vincenzo Cimino, Paola Silvia Morpurgo, Milena Muratori, Laura Plebani, Andrea Bolla, Antonio Rossi, Luciana Vallone, Alessandra Gandolfi, Camilla Tinari, Francesca D'Addio, Moufida Ben Nasr, Cristian Loretelli, Cristiana Scaranna, Rosalia Bellante, Roberto Manfrini, Fabrizio Muratori, Ivano Franzetti, Emanuela Orsi, Carmine Gazzaruso, Renata Ghelardi, Paolo Desenzani, Stefano Genovese, Angela Girelli, Franco Folli, Cesare Berra, Paolo Fiorina. Dapagliflozin acutely improves kidney function in type 2 diabetes mellitus. The PRECARE study.
Pharmacological research.
2022 09; 183(?):106374. doi:
10.1016/j.phrs.2022.106374. [PMID: 35908663] - Da Hea Seo, Young Ju Suh, Yongin Cho, Seong Hee Ahn, Seongha Seo, Seongbin Hong, Yong-Ho Lee, Young Ju Choi, Eunjig Lee, So Hun Kim. Effect of Dapagliflozin in Combination with Lobeglitazone and Metformin in Korean Patients with Type 2 Diabetes in Real-World Clinical Practice.
Yonsei medical journal.
2022 Sep; 63(9):825-833. doi:
10.3349/ymj.2022.63.9.825. [PMID: 36031782] - Azza Mohammed Hafez El Medany, Sami Hussein Mahmoud Hammadi, Hoda Mahmoud Khalifa, Rasha Abdelmawla Ghazala, Hend Samir Zakaria Mohammed. The vascular impact of dapagliflozin, liraglutide, and atorvastatin alone or in combinations in type 2 diabetic rat model.
Fundamental & clinical pharmacology.
2022 Aug; 36(4):731-741. doi:
10.1111/fcp.12765. [PMID: 35106814] - Taha Sen, Rosalie Scholtes, Peter J Greasley, David Z I Cherney, Claire C J Dekkers, Marc Vervloet, Alexander H J Danser, Sean J Barbour, Cecilia Karlsson, Ann Hammarstedt, Qiang Li, Gozewijn D Laverman, Petter Bjornstad, Daniel H van Raalte, Hiddo J L Heerspink. Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMOND.
Diabetes, obesity & metabolism.
2022 Aug; 24(8):1578-1587. doi:
10.1111/dom.14729. [PMID: 35478433] - Fang-Fang Ren, Zuo-Yi Xie, Yi-Na Jiang, Xuan Guan, Qiao-Ying Chen, Teng-Fang Lai, Lei Li. Dapagliflozin attenuates pressure overload-induced myocardial remodeling in mice via activating SIRT1 and inhibiting endoplasmic reticulum stress.
Acta pharmacologica Sinica.
2022 Jul; 43(7):1721-1732. doi:
10.1038/s41401-021-00805-2. [PMID: 34853445] - Simke W Waijer, Priya Vart, David Z I Cherney, Glenn M Chertow, Niels Jongs, Anna Maria Langkilde, Johannes F E Mann, Ofri Mosenzon, John J V McMurray, Peter Rossing, Ricardo Correa-Rotter, Bergur V Stefansson, Robert D Toto, David C Wheeler, Hiddo J L Heerspink. Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.
Diabetologia.
2022 07; 65(7):1085-1097. doi:
10.1007/s00125-022-05694-6. [PMID: 35445820] - Mariam Alatrach, Christina Agyin, Carolina Solis-Herrera, Olga Lavryneko, John Adams, Amalia Gastaldelli, Curtis Triplitt, Ralph A DeFronzo, Eugenio Cersosimo. Dapagliflozin Impairs the Suppression of Endogenous Glucose Production in Type 2 Diabetes Following Oral Glucose.
Diabetes care.
2022 06; 45(6):1372-1380. doi:
10.2337/dc21-1798. [PMID: 35235659] - Roselle A Herring, Fariba Shojaee-Moradie, Mary Stevenage, Iain Parsons, Nicola Jackson, Jeewaka Mendis, Benita Middleton, A Margot Umpleby, Barbara A Fielding, Melanie Davies, David L Russell-Jones. The SGLT2 Inhibitor Dapagliflozin Increases the Oxidation of Ingested Fatty Acids to Ketones in Type 2 Diabetes.
Diabetes care.
2022 06; 45(6):1408-1415. doi:
10.2337/dc21-2043. [PMID: 35312749] - Xu Huang, Xiaoxu Guo, Gaoliang Yan, Yang Zhang, Yuyu Yao, Yong Qiao, Dong Wang, Gecai Chen, Weiwei Zhang, Chengchun Tang, Feng Cao. Dapagliflozin Attenuates Contrast-induced Acute Kidney Injury by Regulating the HIF-1α/HE4/NF-κB Pathway.
Journal of cardiovascular pharmacology.
2022 06; 79(6):904-913. doi:
10.1097/fjc.0000000000001268. [PMID: 35383661] - E Belen, I P Canbolat, G Yigittürk, Ö Cetinarslan, C S Akdeniz, M Karaca, M Sönmez, O Erbas. Cardio-protective effect of dapagliflozin against doxorubicin induced cardiomyopathy in rats.
European review for medical and pharmacological sciences.
2022 Jun; 26(12):4403-4408. doi:
10.26355/eurrev_202206_29079. [PMID: 35776041] - Remo H M Furtado, Itamar Raz, Erica L Goodrich, Sabina A Murphy, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, John P H Wilding, Philip Aylward, Anthony J Dalby, Mikael Dellborg, Doina Dimulescu, José C Nicolau, Anthonius J M Oude Ophuis, Avivit Cahn, Ofri Mosenzon, Ingrid Gause-Nilsson, Anna Maria Langkilde, Marc S Sabatine, Stephen D Wiviott. Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial.
Circulation.
2022 05; 145(21):1581-1591. doi:
10.1161/circulationaha.121.058103. [PMID: 35510542] - Glenn M Chertow, Priya Vart, Niels Jongs, Anna Maria Langkilde, John J V McMurray, Ricardo Correa-Rotter, Peter Rossing, C David Sjöström, Bergur V Stefansson, Robert D Toto, David C Wheeler, Hiddo J L Heerspink. Quételet (body mass) index and effects of dapagliflozin in chronic kidney disease.
Diabetes, obesity & metabolism.
2022 05; 24(5):827-837. doi:
10.1111/dom.14641. [PMID: 34984791] - Kristina Charaya, Dmitry Shchekochikhin, Denis Andreev, Irina Dyachuk, Svetlana Tarasenko, Maria Poltavskaya, Dinara Mesitskaya, Alexandra Bogdanova, Natalia Ananicheva, Alina Kuzub. Impact of dapagliflozin treatment on renal function and diuretics use in acute heart failure: a pilot study.
Open heart.
2022 05; 9(1):. doi:
10.1136/openhrt-2021-001936. [PMID: 35609943] - Su Ern Yeoh, Kieran F Docherty, Pardeep S Jhund, Mark C Petrie, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Olof Bengtsson, David W Boulton, Peter J Greasley, Anna Maria Langkilde, Mikaela Sjöstrand, Scott D Solomon, John J V McMurray. Relationship of Dapagliflozin With Serum Sodium: Findings From the DAPA-HF Trial.
JACC. Heart failure.
2022 05; 10(5):306-318. doi:
10.1016/j.jchf.2022.01.019. [PMID: 35483792] - Qianyi Luo, Sameer P Leley, Erika Bello, Hurshdeep Dhami, Deepa Mathew, Ashay Dilip Bhatwadekar. Dapagliflozin protects neural and vascular dysfunction of the retina in diabetes.
BMJ open diabetes research & care.
2022 05; 10(3):. doi:
10.1136/bmjdrc-2022-002801. [PMID: 35577387] - Kalie L Tommerdahl, Robert G Nelson, Petter Bjornstad. Dapagliflozin in young people with type 2 diabetes.
The lancet. Diabetes & endocrinology.
2022 05; 10(5):303-304. doi:
10.1016/s2213-8587(22)00075-4. [PMID: 35378070] - Katherine R Tuttle. Learnings from Throwing Paint at the Wall for COVID-19 with an SGLT2 Inhibitor.
Clinical journal of the American Society of Nephrology : CJASN.
2022 05; 17(5):628-630. doi:
10.2215/cjn.03250322. [PMID: 35483735] - Charlotte C van Ruiten, Mark M Smits, Megan D Kok, Erik H Serné, Daniël H van Raalte, Mark H H Kramer, Max Nieuwdorp, Richard G IJzerman. Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial.
Cardiovascular diabetology.
2022 04; 21(1):63. doi:
10.1186/s12933-022-01492-x. [PMID: 35484607] - Yi Tang, Siyuan Tan, Minqi Li, Yijin Tang, Xiaoping Xu, Qinghai Zhang, Qinghua Fu, Mingxiang Tang, Jin He, Yi Zhang, Zhaofen Zheng, Jianqiang Peng, Tengteng Zhu, Wenlin Xie. Dapagliflozin, sildenafil and their combination in monocrotaline-induced pulmonary arterial hypertension.
BMC pulmonary medicine.
2022 Apr; 22(1):142. doi:
10.1186/s12890-022-01939-7. [PMID: 35413880] - Benjamin Burggraaf, Nadine M C Pouw, Salvador Fernández Arroyo, Leonie C van Vark-van der Zee, Gert-Jan M van de Geijn, Erwin Birnie, Jeannine Huisbrink, Ellen M van der Zwan, Wouter W de Herder, Monique T Mulder, Patrick C N Rensen, Manuel Castro Cabezas. Effects of dapagliflozin on postprandial lipid metabolism in type 2 diabetes mellitus.
European journal of endocrinology.
2022 Apr; 186(5):597-605. doi:
10.1530/eje-21-1270. [PMID: 35312632] - Laongdao Thongnak, Nattavadee Pengrattanachot, Sasivimon Promsan, Nichakorn Phengpol, Prempree Sutthasupha, Varanuj Chatsudthipong, Anusorn Lungkaphin. The combination of dapagliflozin and statins ameliorates renal injury through attenuating the activation of inflammasome-mediated autophagy in insulin-resistant rats.
Journal of biochemical and molecular toxicology.
2022 Apr; 36(4):e22978. doi:
10.1002/jbt.22978. [PMID: 34939712] - Hala El-Safty, Ashraf Ismail, Rania M Abdelsalam, Ayman E El-Sahar, Muhammed A Saad. Dapagliflozin diminishes memory and cognition impairment in Streptozotocin induced diabetes through its effect on Wnt/β-Catenin and CREB pathway.
Brain research bulletin.
2022 04; 181(?):109-120. doi:
10.1016/j.brainresbull.2022.01.017. [PMID: 35093471] - Kayo Horibe, Katsutaro Morino, Itsuko Miyazawa, Sachiko Tanaka-Mizuno, Keiko Kondo, Daisuke Sato, Natsuko Ohashi, Shogo Ida, Tsuyoshi Yanagimachi, Masahiro Yoshimura, Ryuta Itoh, Kiyoshi Murata, Katsuyuki Miura, Hisatomi Arima, Yukihiro Fujita, Satoshi Ugi, Hiroshi Maegawa. Metabolic changes induced by dapagliflozin, an SGLT2 inhibitor, in Japanese patients with type 2 diabetes treated by oral anti-diabetic agents: A randomized, clinical trial.
Diabetes research and clinical practice.
2022 Apr; 186(?):109781. doi:
10.1016/j.diabres.2022.109781. [PMID: 35181350] - Xuezhong Xu, Wen Xu, Qingqing Zhuo, Yan Yan. The efficacy and safety of dapagliflozin combined with oral hypoglycemic agents in patients with type 2 diabetes: a systematic review and meta-analysis.
Annals of palliative medicine.
2022 Mar; 11(3):1028-1037. doi:
10.21037/apm-22-121. [PMID: 35365032] - Reem M Hazem, Ahmed Z Ibrahim, Dina A Ali, Yasser M Moustafa. Dapagliflozin improves steatohepatitis in diabetic rats via inhibition of oxidative stress and inflammation.
International immunopharmacology.
2022 Mar; 104(?):108503. doi:
10.1016/j.intimp.2021.108503. [PMID: 34998036] - Kristina Wallenius, Tobias Kroon, Therese Hagstedt, Lars Löfgren, Maria Sörhede-Winzell, Jeremie Boucher, Daniel Lindén, Nicholas D Oakes. The SGLT2 inhibitor dapagliflozin promotes systemic FFA mobilization, enhances hepatic β-oxidation, and induces ketosis.
Journal of lipid research.
2022 03; 63(3):100176. doi:
10.1016/j.jlr.2022.100176. [PMID: 35120993] - Kriengsak Vareesangthip, Chaicharn Deerochanawong, Dittaya Thongsuk, Nuch Pojchaijongdee, Unchalee Permsuwan. Cost-Utility Analysis of Dapagliflozin as an Add-on to Standard of Care for Patients with Chronic Kidney Disease in Thailand.
Advances in therapy.
2022 03; 39(3):1279-1292. doi:
10.1007/s12325-021-02037-6. [PMID: 35038121] - Ke He, Jingxin Li, Wang Xi, Jun Ge, Jingna Sun, Zeng Jing. Dapagliflozin for nonalcoholic fatty liver disease: A systematic review and meta-analysis.
Diabetes research and clinical practice.
2022 Mar; 185(?):109791. doi:
10.1016/j.diabres.2022.109791. [PMID: 35202771] - Hyuk Jun Cho, Mi Ran Woo, Jung Hyun Cho, Yong Kim, Han-Gon Choi. Novel dapagliflozin di-L-proline cocrystal-loaded tablet: preparation, physicochemical characterization, and pharmacokinetics in beagle dogs and mini-pigs.
Pharmaceutical development and technology.
2022 Mar; 27(3):331-340. doi:
10.1080/10837450.2022.2052320. [PMID: 35264063] - Ignacio J Amat-Santos, Juan P Sánchez-Luna, Emad Abu-Assi, María Melendo-Viu, Ignacio Cruz-Gonzalez, Luis Nombela-Franco, Antonio J Muñoz-Garcí, Sergio G Blas, Jose M de la Torre Hernandez, Rafael Romaguera, Ángel Sánchez-Recalde, José L Diez-Gil, Diego Lopez-Otero, Livia Gheorge, Borja Ibáñez, Andrés Iñiguez-Romo, Sergio Raposeiras-Roubín. Rationale and design of the Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) randomized trial.
European journal of heart failure.
2022 03; 24(3):581-588. doi:
10.1002/ejhf.2370. [PMID: 34693613] - Diala Alhaj Moustafa, Zainab Imran, Roua Ismail, Menatallah Rayan, Alain-Pierre Gadeau, Hussein Eldassouki, Nabeel Abdulrahman, Fatima Mraiche. Evaluating the effects of sodium glucose co-transporter -2 inhibitors from a renin-angiotensin-aldosterone system perspective in patients infected with COVID-19: contextualizing findings from the dapagliflozin in respiratory failure in patients with COVID-19 study.
Molecular biology reports.
2022 Mar; 49(3):2321-2324. doi:
10.1007/s11033-022-07183-w. [PMID: 35102475] - Mikhail N Kosiborod, Russell Esterline, Jan Oscarsson, Samvel B Gasparyan, Remo H M Furtado, Subodh Verma, Otavio Berwanger. Dapagliflozin in patients with COVID-19: mind the kidneys - Authors' reply.
The lancet. Diabetes & endocrinology.
2022 02; 10(2):98-99. doi:
10.1016/s2213-8587(21)00326-0. [PMID: 34921753] - Michael S Kelly. An update on dapagliflozin for chronic kidney disease.
Drugs of today (Barcelona, Spain : 1998).
2022 Feb; 58(2):69-75. doi:
10.1358/dot.2022.58.2.3369188. [PMID: 35188141] - Thiago Reis, Marlies Ostermann, Alexander Zarbock, John A Kellum, Claudio Ronco. Dapagliflozin in patients with COVID-19: mind the kidneys.
The lancet. Diabetes & endocrinology.
2022 02; 10(2):97-98. doi:
10.1016/s2213-8587(21)00329-6. [PMID: 34921752] - Yi Song, Feng Guo, Yifan Liu, Fengjuan Huang, Xunjie Fan, Lin Zhao, Guijun Qin. Identification of circular RNAs and functional competing endogenous RNA networks in human proximal tubular epithelial cells treated with sodium-glucose cotransporter 2 inhibitor dapagliflozin in diabetic kidney disease.
Bioengineered.
2022 02; 13(2):3911-3929. doi:
10.1080/21655979.2022.2031391. [PMID: 35129424] - Arne Gessner, Anna Gemeinhardt, Agnes Bosch, Dennis Kannenkeril, Christian Staerk, Andreas Mayr, Martin F Fromm, Roland E Schmieder, Renke Maas. Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers.
Cardiovascular diabetology.
2022 01; 21(1):4. doi:
10.1186/s12933-021-01436-x. [PMID: 34991562] - Mohamed A Abdelaziz, Moataz Shaldam, Ramadan A El-Domany, Fathalla Belal. Multi-Spectroscopic, thermodynamic and molecular dynamic simulation studies for investigation of interaction of dapagliflozin with bovine serum albumin.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.
2022 Jan; 264(?):120298. doi:
10.1016/j.saa.2021.120298. [PMID: 34464920] - Peter Rossing, Silvio E Inzucchi, Priya Vart, Niels Jongs, Kieran F Docherty, Pardeep S Jhund, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Scott D Solomon, David L DeMets, Olof Bengtsson, Magnus Lindberg, Anna Maria Langkilde, Mikaela Sjöstrand, Bergur V Stefansson, Cecilia Karlsson, Glenn M Chertow, Fan Fan Hou, Ricardo Correa-Rotter, Robert D Toto, David C Wheeler, John J V McMurray, Hiddo J L Heerspink. Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials.
The lancet. Diabetes & endocrinology.
2022 01; 10(1):24-34. doi:
10.1016/s2213-8587(21)00295-3. [PMID: 34856173] - Yinhui Li, Hui Li, Liming Dong, Dandan Lin, Lijuan Xu, Pengwei Lou, Deng Zang, Kai Wang, Li Ma. A Network Meta-Analysis of the Dose-Response Effects of Dapagliflozin on Efficacy and Safety in Adults With Type 1 Diabetes.
Frontiers in endocrinology.
2022; 13(?):923376. doi:
10.3389/fendo.2022.923376. [PMID: 35872994] - Zeenat A Shyr, Zihan Yan, Alessandro Ustione, Erin M Egan, Maria S Remedi. SGLT2 inhibitors therapy protects glucotoxicity-induced β-cell failure in a mouse model of human KATP-induced diabetes through mitigation of oxidative and ER stress.
PloS one.
2022; 17(2):e0258054. doi:
10.1371/journal.pone.0258054. [PMID: 35180212] - Ai-Yu Yang, Hung-Chun Chen. Comparative Assessment of the Long-Term Effectiveness and Safety of Dapagliflozin and Empagliflozin as Add-on Therapy to Hypoglycemic Drugs in Patients with Type 2 Diabetes.
Journal of diabetes research.
2022; 2022(?):2420857. doi:
10.1155/2022/2420857. [PMID: 35656359] - Lei Liu, Haizhao Luo, Yunyi Liang, Jielong Tang, Yi Shu. Dapagliflozin Ameliorates STZ-Induced Cardiac Hypertrophy in Type 2 Diabetic Rats by Inhibiting the Calpain-1 Expression and Nuclear Transfer of NF-κB.
Computational and mathematical methods in medicine.
2022; 2022(?):3293054. doi:
10.1155/2022/3293054. [PMID: 35096128] - Zhenyu Bai, Ting Xie, Tianhao Liu, Zedong Chen, Linde Yu, Chao Zhang, Jincheng Luo, Liguo Chen, Xiaoshan Zhao, Ya Xiao. An integrated RNA sequencing and network pharmacology approach reveals the molecular mechanism of dapagliflozin in the treatment of diabetic nephropathy.
Frontiers in endocrinology.
2022; 13(?):967822. doi:
10.3389/fendo.2022.967822. [PMID: 36213291] - Daisuke Sato, Takao Nakamura, Jota Amarume, Mizuna Yano, Yuta Umehara, Atsuyoshi Nishina, Kazuhiko Tsutsumi, Zhonggang Feng, Masataka Kusunoki. Effects of Dapagliflozin on Adipose and Liver Fatty Acid Composition and mRNA Expression Involved in Lipid Metabolism in High-Fat-Fed Rats.
Endocrine, metabolic & immune disorders drug targets.
2022; 22(9):944-953. doi:
10.2174/1871530322666220307153618. [PMID: 35255800] - Hao Zhaohu, Huang Xiao, Shao Hailin, He Feng. Efficacy and Safety of Dapagliflozin versus Liraglutide in Patients with Overweight or Obesity and Type 2 Diabetes Mellitus: A Randomised Controlled Clinical Trial in Tianjin, China.
Journal of diabetes research.
2022; 2022(?):4126995. doi:
10.1155/2022/4126995. [PMID: 35990242] - Abolfazl Akbari, Mahdi Rafiee, Thozhukat Sathyapalan, Amirhossein Sahebkar. Impacts of Sodium/Glucose Cotransporter-2 Inhibitors on Circulating Uric Acid Concentrations: A Systematic Review and Meta-Analysis.
Journal of diabetes research.
2022; 2022(?):7520632. doi:
10.1155/2022/7520632. [PMID: 35224108] - Wenhui Dai, Qiaolin Peng. Efficacy of Dapagliflozin Combined with Lifestyle Intervention in Obesity Control.
Computational and mathematical methods in medicine.
2022; 2022(?):7745873. doi:
10.1155/2022/7745873. [PMID: 35602349] - Po-Jui Chi, Chung-Jen Lee, Yi-Jen Hsieh, Chia-Wen Lu, Bang-Gee Hsu. Dapagliflozin Ameliorates Lipopolysaccharide Related Acute Kidney Injury in Mice with Streptozotocin-induced Diabetes Mellitus.
International journal of medical sciences.
2022; 19(4):729-739. doi:
10.7150/ijms.69031. [PMID: 35582427] - Hiddo J L Heerspink, David Cherney, Douwe Postmus, Bergur V Stefánsson, Glenn M Chertow, Jamie P Dwyer, Tom Greene, Mikhail Kosiborod, Anna Maria Langkilde, John J V McMurray, Ricardo Correa-Rotter, Peter Rossing, C David Sjöström, Robert D Toto, David C Wheeler. A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function.
Kidney international.
2022 01; 101(1):174-184. doi:
10.1016/j.kint.2021.09.005. [PMID: 34560136] - Qingqing Ke, Caifeng Shi, Yunhui Lv, Lulu Wang, Jing Luo, Lei Jiang, Junwei Yang, Yang Zhou. SGLT2 inhibitor counteracts NLRP3 inflammasome via tubular metabolite itaconate in fibrosis kidney.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
2022 01; 36(1):e22078. doi:
10.1096/fj.202100909rr. [PMID: 34918381] - Adina Braha, Alin Albai, Bogdan Timar, Daniela Cipu, Lucian Vasiluță, Ovidiu Potre, Romulus Timar. Predictors of Epicardial Fat Volume Decrease after Dapagliflozin Treatment in Patients with Type 2 Diabetes.
Medicina (Kaunas, Lithuania).
2021 Dec; 58(1):. doi:
10.3390/medicina58010021. [PMID: 35056329] - Lan Cheng, Qianyu Fu, Longhua Zhou, Yuqin Fan, Fenfen Liu, Yuanyuan Fan, Xin Zhang, Weiqing Lin, Xiaohe Wu. Dapagliflozin, metformin, monotherapy or both in patients with metabolic syndrome.
Scientific reports.
2021 12; 11(1):24263. doi:
10.1038/s41598-021-03773-z. [PMID: 34930986] - Martha K Nicholson, Randa Ghazal Asswad, John Ph Wilding. Dapagliflozin for the treatment of type 2 diabetes mellitus - an update.
Expert opinion on pharmacotherapy.
2021 Dec; 22(17):2303-2310. doi:
10.1080/14656566.2021.1953471. [PMID: 34281456] - Tuo Han, Yajie Fan, Jie Gao, Mahreen Fatima, Yali Zhang, Yiming Ding, Liang Bai, Congxia Wang. Sodium glucose cotransporter 2 inhibitor dapagliflozin depressed adiposity and ameliorated hepatic steatosis in high-fat diet induced obese mice.
Adipocyte.
2021 12; 10(1):446-455. doi:
10.1080/21623945.2021.1979277. [PMID: 34550043] - Hwee-Yeong Ng, Foong-Fah Leung, Wei-Hung Kuo, Wen-Chin Lee, Chien-Te Lee. Dapagliflozin and xanthine oxidase inhibitors improve insulin resistance and modulate renal glucose and urate transport in metabolic syndrome.
Clinical and experimental pharmacology & physiology.
2021 12; 48(12):1603-1612. doi:
10.1111/1440-1681.13574. [PMID: 34407232] - Kamyar Kalantar-Zadeh, Srinivasan Beddhu, Csaba P Kovesdy, Holly J Kramer, Denis Fouque. Biologically plausible trends suggesting that a low-protein diet may enhance the effect of flozination caused by the sodium-glucose cotransporter-2 inhibitor dapagliflozin on albuminuria.
Diabetes, obesity & metabolism.
2021 12; 23(12):2825-2826. doi:
10.1111/dom.14524. [PMID: 34387935] - Mohsin Kazi, Abdulmohsen Alqahtani, Ajaz Ahmad, Omar M Noman, Mohammed S Aldughaim, Ali S Alqahtani, Fars K Alanazi. Development and optimization of sitagliptin and dapagliflozin loaded oral self-nanoemulsifying formulation against type 2 diabetes mellitus.
Drug delivery.
2021 Dec; 28(1):100-114. doi:
10.1080/10717544.2020.1859001. [PMID: 33345632] - Eu Jeong Ku, Dong-Hwa Lee, Hyun Jeong Jeon, Tae Keun Oh. Long-term effectiveness and safety of quadruple combination therapy with empagliflozin versus dapagliflozin in patients with type 2 diabetes: 3-year prospective observational study.
Diabetes research and clinical practice.
2021 Dec; 182(?):109123. doi:
10.1016/j.diabres.2021.109123. [PMID: 34740742] - Hwee-Yeong Ng, Wei-Hung Kuo, You-Lin Tain, Foong-Fah Leung, Wen-Chin Lee, Chien-Te Lee. Effect of Dapagliflozin and Magnesium Supplementation on Renal Magnesium Handling and Magnesium Homeostasis in Metabolic Syndrome.
Nutrients.
2021 Nov; 13(11):. doi:
10.3390/nu13114088. [PMID: 34836340] - Niels Jongs, Tom Greene, Glenn M Chertow, John J V McMurray, Anna Maria Langkilde, Ricardo Correa-Rotter, Peter Rossing, C David Sjöström, Bergur V Stefansson, Robert D Toto, David C Wheeler, Hiddo J L Heerspink. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
The lancet. Diabetes & endocrinology.
2021 11; 9(11):755-766. doi:
10.1016/s2213-8587(21)00243-6. [PMID: 34619106] - Noha S Abbas, Yahya Abduh Salim Mohamed, Sayed M Derayea, Mahmoud A Omar, Gamal A Saleh. Simple TLC-spectrodensitometric method for studying lipophilicity and quantitative analysis of hypoglycemic drugs in their binary mixture.
Biomedical chromatography : BMC.
2021 Nov; 35(11):e5154. doi:
10.1002/bmc.5154. [PMID: 33955025] - Vanessa Bedoya Joaqui, Nathalia Buitrago Gómez, Reinaldo Carvajal Ortiz, Luis Miguel Osorio Toro, Jenny Patricia Muñoz Lombo, Carlos Alberto Salgado Cifuentes, Mónica Andrea Morales García, Alín Abreu Lomba. Effectiveness of triple therapy with dapagliflozin add-on to dual therapy over 52 weeks in patients with uncontrolled type 2 diabetes mellitus in a centre of high complexity, Cali-Colombia.
Archives of endocrinology and metabolism.
2021 Nov; 65(1):49-59. doi:
10.20945/2359-3997000000319. [PMID: 33444492] - Hiddo J L Heerspink, Niels Jongs, Glenn M Chertow, Anna Maria Langkilde, John J V McMurray, Ricardo Correa-Rotter, Peter Rossing, C David Sjöström, Bergur V Stefansson, Robert D Toto, David C Wheeler, Tom Greene. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
The lancet. Diabetes & endocrinology.
2021 11; 9(11):743-754. doi:
10.1016/s2213-8587(21)00242-4. [PMID: 34619108] - John J V McMurray, David C Wheeler, Bergur V Stefánsson, Niels Jongs, Douwe Postmus, Ricardo Correa-Rotter, Glenn M Chertow, Fan Fan Hou, Peter Rossing, C David Sjöström, Scott D Solomon, Robert D Toto, Anna Maria Langkilde, Hiddo J L Heerspink. Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure.
JACC. Heart failure.
2021 11; 9(11):807-820. doi:
10.1016/j.jchf.2021.06.017. [PMID: 34446370] - Kieran F Docherty, Pardeep S Jhund, Brian Claggett, João Pedro Ferreira, Olof Bengtsson, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Anna Maria Langkilde, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Mikaela Sjöstrand, Scott D Solomon, John J V McMurray. Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial.
JAMA cardiology.
2021 11; 6(11):1298-1305. doi:
10.1001/jamacardio.2021.2632. [PMID: 34319398] - Janani Rangaswami, Kevin Bryan Lo, Muthiah Vaduganathan, Roy O Mathew. Eligibility for SGLT2 Inhibitors in Heart Failure Without the Race Coefficient for Kidney Function Estimation.
Journal of the American College of Cardiology.
2021 10; 78(16):1669-1670. doi:
10.1016/j.jacc.2021.08.025. [PMID: 34649704] - Guoping Chen, Hong Wang, Wenjing Zhang, Jiaqiang Zhou. Dapagliflozin Reduces Urinary Albumin Excretion by Downregulating the Expression of cAMP, MAPK, and cGMP-PKG Signaling Pathways Associated Genes.
Genetic testing and molecular biomarkers.
2021 Oct; 25(10):627-637. doi:
10.1089/gtmb.2021.0086. [PMID: 34672772] - Karan Matharu, Kiran Chana, Charles J Ferro, Alan M Jones. Polypharmacology of clinical sodium glucose co-transport protein 2 inhibitors and relationship to suspected adverse drug reactions.
Pharmacology research & perspectives.
2021 10; 9(5):e00867. doi:
10.1002/prp2.867. [PMID: 34586753] - Susrichit Phrueksotsai, Kanokwan Pinyopornpanish, Juntima Euathrongchit, Apinya Leerapun, Arintaya Phrommintikul, Supawan Buranapin, Nipon Chattipakorn, Satawat Thongsawat. The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver disease.
Journal of gastroenterology and hepatology.
2021 Oct; 36(10):2952-2959. doi:
10.1111/jgh.15580. [PMID: 34129252] - A M Kabel, S A Salama. Effect of taxifolin/dapagliflozin combination on colistin-induced nephrotoxicity in rats.
Human & experimental toxicology.
2021 Oct; 40(10):1767-1780. doi:
10.1177/09603271211010906. [PMID: 33882723] - Yoshimasa Aso, Masaaki Sagara, Takafumi Niitani, Kanako Kato, Toshie Iijima, Takuya Tomaru, Teruo Jojima, Isao Usui. Serum high-molecular-weight adiponectin and response to dapagliflozin in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Journal of investigative medicine : the official publication of the American Federation for Clinical Research.
2021 10; 69(7):1324-1329. doi:
10.1136/jim-2020-001621. [PMID: 34016738] - Karen E Elkind-Hirsch, N Chappell, Ericka Seidemann, John Storment, Drake Bellanger. Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome.
The Journal of clinical endocrinology and metabolism.
2021 09; 106(10):3019-3033. doi:
10.1210/clinem/dgab408. [PMID: 34097062] - Nora El-Sayed, Yasser M Mostafa, Noha M AboGresha, Amal A M Ahmed, Islam Z Mahmoud, Norhan M El-Sayed. Dapagliflozin attenuates diabetic cardiomyopathy through erythropoietin up-regulation of AKT/JAK/MAPK pathways in streptozotocin-induced diabetic rats.
Chemico-biological interactions.
2021 Sep; 347(?):109617. doi:
10.1016/j.cbi.2021.109617. [PMID: 34391751]